Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.

ABSTRACT:

Objectives

We aimed to investigate the association between polymorphisms located in type I interferon (IFN)-induced genes, genes belonging to the toll-like receptor (TLR) pathway, and genes encoding neurotransmitter receptors and the response to IFN-β treatment in patients with multiple sclerosis (MS).

Methods

In a first or screening phase of the study, 384 polymorphisms were genotyped in 830 patients with MS classified into IFN-β responders (n = 416) and nonresponders (n = 414) according to clinical criteria. In a second or validation phase, the most significant polymorphisms associated with IFN-β response were genotyped in an independent validation cohort of 555 patients with MS (281 IFN-β responders and 274 nonresponders).

Results

Seven single nucleotide polymorphi

SUBMITTER: Bustamante MF 

PROVIDER: S-EPMC4582905 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature